The role of oxidative stress in the onset and progression of diabetes and its complications: A summary of a congress series sponsored by UNESCO-MCBN, the American diabetes association and the German diabetes society

Diabetes/Metabolism Research and Reviews

Volumn 17, Issue 3, 2001, Pages 189-212

  Rosen P ^a   Nawroth, P P ^b   King, G ^c   Moller W ^d   Tritschler, H J ^d   Packer, L ^e  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c JOSLIN DIABETES CENTER   (United States)

^d ASTA MEDICA AG   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diabetes mellitus; Insulin resistance; Neuropathy; Oxidative stress; Vascular complications

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALPHA TOCOPHEROL; ANTIOXIDANT; GLUCOSE TRANSPORTER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; NICOTINAMIDE; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; THIOCTIC ACID; TRANSCRIPTION FACTOR;

ANTIOXIDANT ACTIVITY; CARDIOVASCULAR DISEASE; CELL MEMBRANE; CLINICAL STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DISEASE COURSE; FEMALE; HUMAN; INSULIN RESISTANCE; LONG TERM CARE; MALE; MEDICAL SOCIETY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN TRANSPORT; RAT; REVIEW; SIGNAL TRANSDUCTION; SYMPOSIUM; VASCULAR ENDOTHELIUM;

ANIMALS; CARDIOVASCULAR DISEASES; CONGRESSES; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; DIABETIC NEUROPATHIES; DISEASE PROGRESSION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; TRANSCRIPTION FACTORS;

EID: 0034939115     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.196     Document Type: Review

References (310)

1. Free radicals in medicine. II: Involvement in human disease
2. Free radicals, anti-oxidants and human disease: Where are we now?
3. Antioxidant nutrients and immune functions: Introduction
4. Antioxidants in human health and disease
5. Free radicals in diabetic endothelial cell dysfunction
6. Serum antioxidant activity in diabetes mellitus
7. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor
8. Dysfunction of vascular endothelium in diabetes meliitus
9. Oxygen free radicals abolish endothelium dependent relaxation in diabetic art aorta
10. Oxidised low density lipoproteins: A role in the pathogenesis of atherosclerosis in diabetes?
11. Antioxidant characterization; methodology and mechanism
12. α-Lipoic acid - A metabolic antioxidant
13. Lipoic and dihydrolipoic acid as antioxidants. A critical evaluation
14. Antioxidant defense: Vitamins E and C and carotenoids
15. The antioxidant role of vitamin C
16. Vitamin E in humans: Demand and delivery
17. Antioxidants in relation to lipid peroxidation
18. New horizons in vitamin E research - The vitamin E cycle, biochemistry and clinical applications
19. Alpha-lipoic acid as a biological antioxidant
20. Lipoic acid increases de novo synthesis of cellular glutathione by improving cystinie utilization
21. Strategies of antioxidant defense
22. Oxygen radicals and human disease
23. Chemistry of free radical damage to DNA and nucleoproteins
24. Base modification and strand breakage in isolated calf thymus DNA and in DNA from human skin epidermal keratinocytes exposed to peroxynitrite or 3-morpholinosydnonimine
25. Hypochlorous acid-induced base modification in isolated calf thymus DNA
26. 8-Hydroxydeoxyguanosine as a urinary marker of oxidative DNA damage
27. Beyond cholesterol. Modifications of low-density lipoprotein that increases its atherogenicity
28. Mechanisms of oxidative damage of low density lipoprotein in arteriosclerosis
29. The role of lipid peroxidation and antioxidants in oxidative modification of LDL
30. Lipid peroxidation: Its mechanism, measurement and significance
31. Lipid peroxidation in hyperlipidaemic patients. A study of plasma using an HPLC-based thiobarbituric acid test
32. Automatic determination of hydroperoxides of phosphatidylcholine and phosphatidylethanolamine in human plasma
33. Evaluation of an isoluminol chemiluminescence assay for the detection of hydroperoxides in human blood plasma
34. Measurement of lipid hydroperoxides in normal human blood plasma using HPLC-chemiluminescence linked to a diode array detector for measuring conjugated dienes
35. Quantitative gas chromatography-mass spectrometry isomer-specific measurement of hydroxy fatty acids in biological samples and food as a marker of lipid peroxidation
36. Simultaneous determination of phospholipid hydroperoxides and cholesteryl ester hydroperoxides in human plasma by high-performance liquid chromatography with chemiluminescene detection
37. 2α
38. 2α excretion in man
39. 2-isoprostanes as indicators of non-enzymatic lipid peroxidation in vivo by gas chromatography-mass spectrometry: Development of a solid-phase extraction procedure
40. 2-isoprostanes) in smokers
41. 2-isoprostanes during aortic endothelial cell-mediated oxidation of low density lipoprotein
42. 1-antiproteinase by sulphur-containing radicals derived from penicillamine
43. Oxidative chemistry of peroxynitrite
44. What nitrates tyrosine? Is nitrotyrosine specific as a biomarker of peroxynitite formation in vivo?
45. Radical-mediated protein oxidation. From chemistry to medicine
46. Determination of carbonyl content in oxidatively modified protein
47. Conversion of amino acid residues in proteins and amino acid homopolymers to carbonyl derivates by metal-catalyzed oxidation reactions
48. Oxidative damage to DNA in diabetes mellitus
49. New biomarker evidence of oxidative DNA damage in patients with non-insulin-dependent diabetes mellitus
50. Enhanced serum levels of TBARS in diabetes mellitus
51. Antioxidant status and lipid peroxidation in type II diabetes with and without complications
52. Relation of lipid peroxides to macrovascular disease in type 2 diabetes
53. A comparison of different methods of assessing free radical activity in type 2 diabetes and peripheral vascular disease
54. Lipid peroxide levels of serum lipoprotein fractions of diabetic patients
55. Increased lipid peroxidation in type 2 poorly controlled diabetic patients
56. Increased diene conjugates in diabetic subjects with microangiopathy
57. Plasma oxidisability in subjects with normal glucose tolerance, impaired glucose tolerance and NIDDM
58. 2α levels are elevated in individuals with non-insulin dependent diabetes mellitus
59. Elevated levels of authentic plasma hydroperoxides in NIDDM
60. Relationships between plasma measures of oxidative stress and metabolic control in NIDDM
61. 2α and platelet activation in diabetes mellitus: Effects of improved metabolic control and vitamin E supplementation
62. Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM
63. Oxidation of low density lipoproteins and vitamin E status in non insulin dependent diabetes mellitus (NIDDM)
64. Increased susceptibility of LDL to in vitro oxidation in patients with insulin dependent diabetes mellitus
65. Effects on vitamin E on susceptibility of low-density lipoprotein subfractions to oxidation and protein glycation in NIDDM
66. Increased oxidizability of plasma lipoproteins in diabetic patients can be decreased by probucol therapy and is not due to glycation
67. Glycosylated low-density protein is more sensitive to oxidation: Implications for the diabetic patients
68. Oxidation of low-density lipoprotein in NIDDM: Its relationship to fatty acid composition
69. Enhanced susceptibility of low-density lipoprotein to in vitro oxidation in type 1 and type 2 diabetic patients
70. Increased susceptibility to lipid oxidation of low-density lipoproteins and erythrocyte membranes from diabetic patients
71. Vitamin E Mangel und Oxidierbarkeit der Low-Density-Lipoproteine bei Typ-I- und Typ-II-Diabetes: Einfluβ der Qualität der Stoffwechselkontrolle
72. Impact of concentrations of glycated hemoglobin, alpha-tocopherol, copper, and manganese on oxidation of low-density lipoproteins in patients with type I diabetes, type II diabetes and control subjects
73. Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM
74. Glutathione and its redox system in diabetic polymorphonuclear leukocytes
75. Vitamin C metabolites and microangiopathy in diabetes mellitus
76. Production of 12 HETES and vitamin E status in platelets from type 1 human diabetic subjects
77. Plasma vitamin C affects glucose homeostasis in healthy subjects and in non-insulin-dependent diabetics
78. Reference values for retinol, tocopherol and main carotenoids in serum of control and insulin dependent diabetic Spanish subjects
79. Antioxidant status in patients with uncomplicated insulin-dependent and non insulin-dependent diabetes mellitus
80. 7-Ketocholesterol, a specific indicator of lipoprotein oxidation, and malondialdehyde in non-insulin dependent diabetes and peripheral vascular disease
81. Disturbed handling of ascorbic acid in diabetic patients with and without microagiopathy during high dose ascorbate supplementation
82. Diabetes mellitus, lipid peroxidation and antioxidant status in rural patients
83. Increased risk of non-insulin dependent diabetes mellitus at low plasma vitamin E concentrations: A four year follow up study in men
84. Negative association between erythrocytes, reduced glutathione concentration and diabetic complications
85. Alpha-Tocopherolaufnahme und -zufuhr bei Typ-II-Diabetikern
86. Vitamin E in diabetes: Increased oxidative stress and its prevention as a strategy to prevent vascular complications?
87. RRR-alpha-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus
88. Alpha-lipoic acid decreases oxidative stress in diabetic patients with poor glycemic control and albuminuria
89. Effect of alpha tocopherol on LDL oxidation and glycation: In vitro and in vivo studies
90. Generation of reactive oxygen intermediates, activation of NFkappaB, and induction of apoptosis in human endothelial cells by glucose: Role of nitric oxide synthase?
91. 2+ /EDRF signaling are due to generation of superoxide anions
92. 2+ response and EDRF formation in vascular endothelial cells
93. Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis
94. Role of oxygen derived radicals for vascular dysfunction in the diabetic heart: Prevention by α-tocopherol?
95. Endothelial dysfunction in mesenteric resistance arteries of diabetic rats: Role of free radicals
96. Elevated glucose promotes generation of endothelium-dependent vasoconstrictive prostanoids in rabbit aorta
97. Free radical generation by early glycation products: A mechanism for accelerated arteriogenesis in diabetes
98. Superoxide production from non-enzymatically glycated protein
99. Interaction of advanced glycation end products with their endothelial cell receptor leads to enhanced expression of VCAM-1: A mechanism for augmented monocyte-vessel wall interactions in diabetes
100. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions
101. Diabetes mellitus and free radicals
102. Protein glycation and oxidative stress in diabetes mellitus and ageing
103. 2 in human umbilical vein endothelial cells cultured in high glucose medium
104. Acute hyperglycaemia and oxidative stress generation
105. Endothelial relaxation is disturbed by oxidative stress in the diabetic heart: The influence of tocopherol as antioxidant
106. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions
107. Oxidative stress and diabetic vascular complications
108. Role of oxidative stress in development of complications in diabetes
109. Identification of carboxymethyllysine as a degradation product of fructose-lysine in glycosylated protein
110. Glycation, glycoxydation, and crosslinking of collagen by glucose. Kinetics, mechanisms and inhibition of late stages of the Maillard reaction
111. ε-lysino)-lactic acid from model compounds and glycated proteins
112. Diabetes mellitus and its degenerative complications: A prospective study of 4400 patients observed between 1947 and 1973
113. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population based cohort: The Rochester Diabetic Neuropathy Study
114. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
115. The effect of intensive diabetes therapy on the development and progression of neuropathy
116. Intensive blood-glucose control with sulponylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
117. Pathogenesis and prevention of diabetic neuropathy
118. Diabetic neuropathy
119. Osmotically induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy
120. Sorbitol, phosphoinositols and sodium-potassium-ATPase in the pathogenesis of diabetic complications N
121. Neurovascular dysfunction in diabetic rats: Potential contribution of autooxidation and free radicals examined using transition metal chelating agents
122. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy
123. The roles of oxidative stress and antioxidant treatment in experimental diabetic polyneuropathy
124. Nerve blood flow and oxygen delivery in normal, diabetic, and ischemic neuropathy
125. Oxygen free radical effects in sciatic nerve in experimental diabetes
126. Impaired vasoreactivity to nitic oxide in experimental diabetic neuropathy
127. Nerve blood flow in early experimental diabetes in rats: Relation to conduction deficits
128. Hypoxic neuropathy relevance to human diabetic neuropathy
129. Neuropathology and blood flow of nerve, spinal roots and dorsal root ganglia in long-standing diabetic rats
130. Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and diabetic rats
131. Effects of anti-oxidant treatment on sciatic nerve dysfunction in streptozotocin-induced diabetic rats. Comparison with essential fatty acids
132. Effects of α-lipoic acid on neurovascular function in diabetic rats: Interaction with essential fatty acids
133. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy
134. Alpha-lipoic acid: Antioxidant potency against lipid peroxydation of neural tissues in vitro, and implications for diabetic neuropathy
135. Role of neurotrophins in diabetic neuropathy and treatment with nerve growth factors
136. Nerve survival and regeneration in diabetes
137. Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: A possible role for NGF in the pathogenesis of diabetic neuropathy
138. Low serum level of nerve growth factor in diabetic neuropathy
139. α-Lipoic acid corrects neuropeptide deficits in diabetic rats via induction of trophic support
140. Efficacy of thioctic acid in the therapy of peripheral diabetic polyneuropathy
141. Randomisierte Studie Thioctsäure gegenüber Vitamin-B-Kombinationspräparat bei Patienten mit diabetischer Polyneuropathie unter besonderer Berücksichtigung des peripheren Neurosystems
142. Zur Wirksamkeit der Thioctsäuretherapie bei Typ I Diabetikern
143. Zur medikamentösen Behandlung der diabetischen Polyneuropathie mit der Alpha-Liponsäure oder Vitamin B-Präparaten
144. 1 bei der diabetischen Polyneuropathie
145. Hochdosierte Langzeit-therapie mit Thioctsäure bei der diabetischen Polyneuropathie: Ergebnisse einer kontrollierten randomisierten Studie unter besonderer Berücksich-tigung der autonomen Neuropathie
146. The ALADIN Study Group: Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant α-lipoic acid: A 3-week randomized controlled trial (ALADIN Study)
147. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (α-lipoic acid). A two year multicenter randomized double blind placebo controlled trial (ALADIN II)
148. Oral treatment of symptomatic diabetic polyneuropathy with the antioxidant thioctic acid (α-lipoic acid). A-3 week randomized double-blind placebo-controlled trial
149. Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid. A 7-month multicenter randomized controlled clinical trial (ALADIN III)
150. Effects of treatment with the antioxidant α-lipoic acid on cardiac autonomic neuropathy in NIDDM patients: A 4-month randomized controlled multicenter clinical trial (DEKAN Study)
151. Protein kinase C activation and the development of diabetic complications
152. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: Evidence for involvement of the renin-angiotensin system
153. Vascular superoxide production by NAD(P)H oxidase: Association between endothelial dysfunction and clinical risk factors
154. Oxidative stress in diabetes: Why does hyperglycaemia induce the formation of reactive oxygen species?
155. Short term glucose stimulates the generation of reactive oxygen species, but eliminates free nitric oxide
156. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
157. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamone pathway and induces plasminogen activator inhibitor-1 expression by increasing SP1 glycosylation
158. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor
159. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C
160. Protein kinase C and lipid signaling for sustained cellular responses
161. Diabetic vascular dysfunction: A model of excessive activation of protein kinase C
162. Activation of protein kinase C in glomerular cells in diabetes. Mechanisms and potential link to the pathogenesis of diabetic glomerulopathy
163. Preferential elevation of protein kinase C isoform β II and diacylglycerol levels in aorta and heart of diabetic rats: Differential reversibility to glycemic control by islet cell transplantation
164. Characterization of the mechanisms for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia
165. Normalization of diacylglycerol-protein kinase C activation by vitamin E in aorta of diabetic rats and cultured rat smooth muscle cells exposed to elevated glucose levels
166. Increase in diacylglycerol mass in isolated glomeruli by glucose from de novo synthesis of glycerolipids
167. Characteristics of protein kinase C β isoform activation on the gene expression of transforming growth factor β, extracellular matrix components and prostanoids in the glomeruli of diabetic rats
168. Translocation of protein kinase α and ξ in rat glomerular mesangial cells cultured under high glucose conditions
169. Amelioration of vascular dysfunction in diabetic rats by an oral PKC β inhibitor
170. Vitamin E prevents diabetes-induced abnormal retinal blood flow via the diacylglycerol-protein kinase C pathway
171. Inhibition of cell proliferation by alpha-tocopherol. Role of protein kinase C
172. Specific retinal DAG and PKC-β isoform modulation mimics abnormal retinal hemodynamics in diabetic rats
173. Correlation of diacylglycerol and protein kinase C activity in rat retina to retinal circulation
174. + ATPase defects in diabetic rats
175. Specific retinal DAG and PKC-β isoform modulation mimics abnormal retinal hemodynamics in diabetic rats
176. The celular and molecular mechanisms of diabetic complications
177. Hyperglycemia induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells
178. Diabetic RBC-induced oxidant stress leads to transendothelial migration of monocyte-like HL-60 cells
179. Acure hyperglycaemia depresses arteriolar NO formation in skeletal muscle
180. Hyperglycaemia rapidly suppresses flow-mediated endothelium dependent vasodilation of brachial artery
181. Vascular effects of acute hyperglycaemia in humans are reversed by L-arginine
182. Diabetes mellitus and hypertension: The possible role of hyperglycaemia through oxidative stress
183. The dark side of glucose
184. Advanced glycosylation end products: A new disease marker for diabetes and aging
185. Advanced glycation end products in tissue and the biochemical basis of diabetic complications
186. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept
187. Advanced glycation end products, oxidant stress and vascular lesions
188. Advanced glycation endproducts (AGEs) mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE
189. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties
190. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and arteriosclerotic plaque formation in normal rabbits
191. The receptor for advanced glycation endproducts plays a central role in mediating the effects of advanced glycation endproducts on the development of vascular disease in diabetes mellitus
192. Advanced glycation end products (AGEs) induced activation of NF-κB is suppressed by alpha-lipoic acid in cultured endothelial cells
193. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors binding proteins
194. Endothelial expression of mononuclear leukocyte adhesion molecule during arteriogenesis
195. Insufficient glycemic control increases NF-κB binding activity in peripheral blood mononuclear cells isolated from patients with type-1 diabetes
196. Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy demonstrate increased activation of the oxidative stress sensitive transcription factor NF-κB
197. Advanced Glycation Endproducts (AGEs) und ihr Rezeptor 'RAGE'. Bedeutung bei der Entstehung diabetischer Spätschäden
198. Oxidative stress, NF-κB activation, and late diabetic complications
199. Flow-mediated dilation in 9-11 year old children
200. Endotheliopathy precedes type 2 diabetes
201. Physiology and pathphysiology of nitric oxide
202. A review of alterations in endothelial nitric oxide production in diabetes: Protective role of arginine on endothelial dysfunction
203. Role of EDRF (nitric oxide) in diabetic renal hyperfiltration
204. Abnormal renal hemodynamic response to reduced renal perfusion pressure in diabetic rats: Role of NO
205. Role of endothelium derived nitric oxide in the pathogenesis of the renal hemodynamic changes of experimental diabetes
206. Sequential alterations in glomerular prostaglandin and thromboxane synthesis in diabetic rats: Relationship to the hyperfiltration of early diabetes
207. Glucose-induced protein kinase C activity regulates arachidonic acid release and eicosanid production by cultured glomerular mesangial cells
208. Abnormally increased glomerular filtration rates in short-term insulin treated diabetic subjects
209. Increased kidney size, glomerular filtration rate and renal plasma flow in short-term insulin dependent diabetes
210. Glomerular hemodynamics in experimental diabetes mellitus
211. Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and the ugly
212. Hypercholesterolemia increases endothelial superoxide anion production
213. Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion production
214. High glucose increases the formation of nitrotyrosine as marker of oxidative stress in human endothelial cells
215. Advanced glycation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes
216. Vitamin C improves endothelium-dependent vasodilatation in patients with non-insulin-dependent diabetes mellitus
217. Vitamin C improves endothelium-dependent vasodilatation in forearm resistance vessels of humans with hypercholesterolemia
218. L-2-Oxothizolidine-4-carboxylic acid reverses endothelial dysfunction in patients with coronary artery disease
219. Improvement of endothelial vasomotor dysfunction by treatment with a-tocopherol in patients with high remnant lipoprotein levels
220. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion
221. The role of nitric oxide and cell adhesion molecules on the microcirculation in ischemia-reperfusion
222. Activation of protein kinase C by elevation of glucose concentration: Proposal for a mechanism in the development of diabetic vascular complications
223. Cooperative interaction of GATA-2 and AP1 regulates transcription of endothelin-1 gene
224. Regulation of retinal hemodynamics in diabetic rats by increased expression and action of endothelin-1
225. Vascular endothelial growth factor in ocular fluids of patients with diabetic retinopathy and other retinal disorders
226. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by vascular smooth muscle cells in vitro
227. High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes
228. Expression of transforming growth factor beta 1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: Effects of ACE inhibition
229. Expression of transforming growth factor-beta and type IV collagen in early streptozotocin-induced diabetes
230. Abnormal metabolism of type IV collagen in normotensive non-insulin-dependent diabetes mellitus patients
231. Increased vascular permeability in spontaneously diabetic BB/W rats with mild versus severe streptozotocin-induced diabetes
232. Adenylate cyclase and protein kinase C mediate opposite actions on endothelial junctions
233. Increased endothelial albumin permeability mediated by protein kinase C activation
234. Increased endothelial albumin permeability mediated by protein kinase C activation
235. 2 in rat heart endothelial cells
236. Hypertension-induced end-organ damage: A new transgenic approach to an old problem
237. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key modulator
238. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor
239. Characterization of vascular endothelial growth factor's effect on activation of protein kinase C, its isoforms, and endothelial cell growth
240. Extracellular matrix changes in diabetes mellitus
241. The immunohistopathology of glomerular antigens. II. The glomerular basement membrane, actomyosin, and fibroblast surface antigens in normal, diseased and transplanted human kidneys
242. Glomerular matrix proteins in nodular glomerulosclerosis in association with light chain deposition disease and diabetes mellitus
243. Role for protein kinase C in the mediation of increased fibronectin accumulation by mesangial cells grown in high glucose medium
244. High glucose causes an increase in extracellular matrix proteins in cultured mesangial cells
245. Increased extracellular matrix synthesis and mRNA in mesangial cells grown in high-glucose medium
246. Mechanisms of glucose-enhanced extracellular matrix accumulation in rat glomerular mesangial cells
247. Glycosylated low density lipoprotein is more sensitive to oxidation: Implications for the diabetic patient
248. Glucose enhances type IV collagen production in cultured rat glomerular mesangial cells
249. Pathophysiology of microvascular disease: An overview
250. Protection of human low density lipoprotein from oxidation by vitamin E and the antioxidant network: Interaction with vitamin C and lipoic (thioctic) acid
251. Glycosylated low density lipoprotein is more sensitive to oxidation: Implications for the diabetic patient
252. The effect of α-tocopherol supplementation on LDL oxidation: A dose dependent study
253. Autoantibody against oxidized LDL and progression of carotid arteriosclerosis
254. Antibody against oxidized low-density lipoprotein predicting myocardial infarction
255. Serum antibodies to oxidized lipoprotein and ceroid in chronic periaortitis
256. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology
257. Vitamin E consumption and the risk of coronary disease in women
258. Vitamin E consumption and the risk of coronary heart disease in men
259. Vitamin E and coronary artery disease
260. A randomized controlled trial of vitamin E in patients with coronary diseases: The Cambridge heart antioxidant study (CHAOS)
261. Epidemiologic evidence on vitamin E in the prevention and treatment of cardiovascular disease
262. The antioxidant vitamins and cardiovascular disease. A critical review of epidemiologic and clinical data
263. Oxidant stress reduces insulin responsiveness in 3T3-L1 adipocytes
264. Putative role for oxidative stress in adipocyte and skeletal muscle insulin resistance
265. Oxidative stress and insulin action: Is there a relationship?
266. Evidence for a relationship between free radicals and insulin action in elderly
267. Is oxidative stress the missing link between insulin resistance and atherosclerosis?
268. Oxidative stress and glycemic regulation
269. Diatary factors determining diabetes and impaired glucose tolerance. A 20-year follow-up of the Finnish and Dutch cohorts of the Seven Countries Study
270. Abnormal antioxidant status in impaired glucose tolerance and non-insulin-dependent diabetes mellitus
271. Serum malondialdehyde, insulin, glucose and lipid profile in hypertension
272. Plasma lipid peroxidation and hyperglycemia: A connection through hyperinsulinaemia?
273. Stimulation of glucose utilization by thioctic acid in rat diaphragm incubated in vitro
274. The antioxidant α-lipoic acid enhances insulin-stimulated glucose metabolism in insulin-resistant rat skeletal muscle
275. Stimulation of glucose uptake by the natural coenzyme α-lipoic acid/thioctic acid
276. Stimulation by α-lipoic acid of glucose transporter activity in skeletal muscle of lean and obese zucker rats
277. Differential effects of lipoic acid stereoisomeres on glucose metabolism in insulin-resistant skeletal muscle
278. The influence of thioctic acid on metabolism and function of the diabetic heart
279. Lipoic acid reduces glycemia and increases muscle GLUT 4 content in streptozotocin-diabetic rats
280. Improvement of insulin-stimulated glucose-disposal in type 2 diabetes after repeated parenteral administration of thioctic acid
281. Effect of acute infusion of thioctic acid on oxidative and non oxidative metabolism in obese subjects with NIDDM
282. Oral administration of rac-α-lipoic acid modulates insulin sensitivity in patients with type 2 diabetes. A placebo-controlled pilot trial
283. α-Lipoic acid enhances glucose disposal in patients with type 2 diabetes
284. Alpha lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type II diabetes
285. Pharmacologic doses of vitamin E improve insulin action in healthy subjects and non-insulin-dependent diabetic patients
286. Daily vitamin E supplements improve metabolic control but not insulin secretion in elderly type II diabetic patients
287. Pharmacological doses of vitamin E and insulin action in elderly subjects
288. Chronic intake of pharmacological doses of vitamin E might be useful in the therapy of elderly patients with coronary heart disease
289. Metabolic benefits deriving from chronic vitamin C supplementation in aged non-insulin dependent diabetics
290. Plasma vitamin C affects glucose homeostasis in healthy subjects and non-insulin-dependent diabetics
291. Glutathione effects on insulin resistance in non-insulin-dependent diabetes mellitus
292. L-Arginine but not D-arginine stimulates insulin-mediated glucose-uptake
293. The role of interleukin-1 in the pathogenesis of IDDM
294. The harmony of the spheres: Inducible nitric oxide synthase and related genes in pancreatic beta cells
295. The murine autoimmune diabetes model: NOD and related strains
296. Checkpoints in the progression of autoimmune disease: Lessons from diabetes models
297. Superoxide dismutase, catalase and scavangers of hydroxyl radical protect against the toxic action of alloxan on pancreatic islet cells in vitro
298. Determinants of the selective toxicity of alloxan to the pancreatic beta cell
299. 2 as mediator for DNA fragmentation
300. CuZn-superoxide disputes, Mn-superoxide dismutase, catalase and glutathione peroxidase in pancreatic islets and other tissues in the mouse
301. Superoxide dismutase in human islets of Langerhans
302. Antioxidant enzyme activities in IDD prone and IDD resistant mice: A comparative study
303. Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues
304. Preventive and therapeutic effects of large-dose nicotinamide injections on diabetes associated with insulitis
305. The use of nicotinamide in the prevention of type 1 diabetes
306. Vitamin E delays diabetes onset in the non-obese diabetic mouse
307. Oxidative stress and pancreatic β-cell destruction in insulin dependent diabetes mellitus